Use of the soluble form of AXL in the diagnosis and/or prognosis of heart failure syndrome

Abstract

[EN] The present invention refers to a method for diagnosing and/or prognosing a heart failure syndrome (HF), which comprises the step of measuring, in vitro, the amount of the soluble form of AXL (sAXL) in a test sample. The invention furthermore provides methods for deciding or recommending whether to initiate a medical regimen, as well as for determining the efficacy of said medical regimen. The invention also provides the use of sAXL as a marker for the diagnosis and/or prognosis of HF sAXL is stable in serum and is differentially expressed in controls and people suffering from HF.

[ES] Método para diagnosticar y/o pronosticar un síndrome de insuficiencia cardíaca (IC), comprendiendo dicho método la etapa de medir, in vitro, la cantidad de la forma soluble de AXL (sAXL) en una muestra de prueba.